Skip to main content

Completed

Medical Student Education Program (MSE)

No Applicants // Limit: 1 (COM-T) // Tickets Available: 1 

Limiting Language
You may not submit more than one application. If you submit more than one application, we will only accept the last on-time submission.


Purpose
The purpose of the Medical Student Education (MSE) Program is to provide support to public medical schools in states ranked in the top quartile for projected primary care provider shortages. to expand or enhance education for medical students preparing to become physicians. This expansion can include funding for direct student supports which help students be successful in medical school, as well as for infrastructure development, maintenance, equipment, and minor renovations or alterations. The program is designed to prepare and encourage medical students to choose residencies and careers in primary care and serve Tribal, rural and other areas with primary care provider shortages in those states after they complete their residency.

  • Increase the number of primary care physicians practicing in states with a projected primary care physician shortage, particularly in rural Tribal and other areas with primary care provider shortages.

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.

Purpose
This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a consortium of clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts

The RCC will lead, manage, and harmonize efforts for the Consortium including 1) providing management and administrative support; 2) providing leadership and expertise on statistical design and analysis, 3) providing research coordination with a central laboratory, 4) harmonizing data collection methods and use of common data elements, 5) developing the database; 6) conducting data management and data analyses for Consortium studies; and 7) fostering research collaborations. This NOFO uses a cooperative agreement mechanism (U24) and runs in parallel with a companion NOFO (RFA-DK-27-121).

Full sponsor guidelines are linked here. 
 

Funding Type
External Deadline
10/9/2026

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.


Purpose
This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs.  Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts. 

Full sponsor guidelines are linked here. 

Funding Type
External Deadline
10/9/2026

Rural Cooperative Development Grants

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language 
An eligible institution may not submit more than one application to this program as a lead institution. This includes applications from subordinate units under a parent institution. Additionally, eligible recipients may only receive funds for one award at a time. Prospective applicants are advised to contact their institutional sponsored projects office regarding processes used to select proposals for submission. For RFAP purposes, ‘parent institution’ refers to the single, legally distinct institution of higher education that oversees its colleges, schools, and departments. A separate UEI by itself does not automatically make a campus or unit a different institution. Some campuses, divisions, or administrative units within a university system may maintain their own UEIs for grants management purposes while still operating under the governance, accreditation, and legal identity of a single parent institution. In such cases, the parent institution, not the UEI, is the controlling factor in determining the one application limit. The one application limit applies to all subordinate units under the same institution. However, university systems with multiple independently accredited and governed institutions may submit one application per institution within the system. A multi campus university system may submit more than one application only if each campus is recognized as a distinct institution based on its own independent accreditation, governance structure, and institutional identity. Institutions that have received congressionally directed funding for research facility projects are not excluded from participation in this program. Such institutions may submit applications and compete for additional projects under this competitive funding opportunity. 

Cost Sharing Requirements
Applicants MUST provide at minimum a 1:1 matching contribution on a dollar-for-dollar basis for all Federal funds awarded under the RFAP. The non-Federal share must be paid in cash and may include funding from private sources or from units of State or local government. In-kind matching will not be considered. See 7 U.S.C. 390a(c)(2)(A). The full match amount must be budgeted in the application, with sources of funding clearly disclosed. Recipients may phase matching contributions, potentially synchronized with project construction milestones, or raise additional funds during the project period, provided that the Authorized Representative signs the award, thereby attesting to fulfill all match commitments. Matching costs must be incurred during the federal award period, align with 2 CFR 200.306 requirements (verifiable, allowable, not double counted, and included in the approved budget), and be properly documented and reported cumulatively via the SF425 Federal Financial Reports throughout and at the conclusion of the project Consistent with 48 U.S.C. 1469a, notwithstanding any other provision of law, in the case of American Samoa, Guam, the Virgin Islands, the Federated States of Micronesia, and the Northern Mariana Islands, NIFA will waive any requirement for local matching funds under $200,000 (including in-kind contributions). 

Executive Summary
This notice identifies the objectives for RCDG program projects, deadlines, funding information, eligibility criteria for projects and applicants, and application forms and associated instructions. NIFA requests applications for grants under the RCDG program for FY 2026 to improve the economic condition of rural areas by helping nonprofit organizations who in turn provide technical assistance to start, expand, or improve cooperatives and mutually owned businesses in rural areas. This notice is being issued to allow applicants sufficient time to leverage financing and prepare and submit their applications.  

Estimated funding amounts are not guaranteed and are subject to the availability of appropriated funds.

FY 2026 Susan Harwood Training Grant Program (Targeted Topic Training and Training and Educational Materials Development Grants)

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language
If an organization submits multiple applications for this or other Harwood funding opportunities, OSHA will review the last viable application package submitted.

Grant Types

  • Targeted Topic Training 
    Supports educational programs that identify and prevent workplace hazards and requires applicants to conduct training on OSHA-designated workplace safety and health hazards
  • Training and Educational Materials Development
    Supports the.development of quality, classroom-ready training and educational materials that identify and prevent workplace hazards.

     

Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional)

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language
Only one application per institution (normally identified by having a unique entity identifier (UEI) number or NIH IPF number) is allowed.

Purpose
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for the Atopic Dermatitis Research Network (ADRN) program. The ADRN program will support Centers that integrate clinical and translational research to improve our understanding and management of atopic dermatitis with emphasis on chronic skin inflammation and the defense mechanisms of the skin.

Full sponsor guidelines are linked here. 

Funding Type
External Deadline
9/24/2026

Seed Instrumentation Support (SIS) Program (S10 Clinical Trial Not Allowed)

Institutionally Coordinated, please contact limited submissions if you are intersted in applying for the September 2026 deadline. 

Upcoming Webinar
July 8, 2026, at 1:00 pm (EST).

Please register using the link below to secure your spot.
https://scgcorp.zoom.us/webinar/register/WN_yoQC9j2mSAWyu7HcCxD8Dw#/registration 

Limiting Language
Applicant organizations may submit only one application, provided that the type of instrument does not currently exist in the applicant organization (identified by UEI).

Purpose
This Notice of Funding Opportunity (NOFO) aims to build new research capacity and develop a sustainable research program by supporting the purchase of a single commercially available biomedical research instrument currently unavailable in the institution. Instruments funded through this program must be shared among the users to create new research opportunities, enable reproducible data generation, encourage collaborative research and training, and strengthen long-term research capabilities. The minimum award is $50,000. While there is no limit on the total cost of the instrument, the maximum award is $400,000.

Research Category
External Deadline
9/25/2026

Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)

Institutionally Coordinated, please contact limited submissions if you are intersted in applying for the July 2026 deadline. 

Per NIH, proposals submitted to the 6/1/2026 SIG deadline should not be resubmitted to the 7/27/2026 deadline. 

Limiting Language
The University of Arizona may submit more than one proposal provided that each application is scientifically distinct. This is an Institutionally Coordinated Submission. 

Purpose
This Notice of Funding Opportunity (NOFO) announces the restructured Shared Instrumentation Grant (SIG) Program that consolidates three existing shared-use instrumentation programs, i.e., the Shared Instrumentation Grant program, the High-End Instrumentation Grant program, and the Basic Instrumentation Grant program. The NOFO invites applications from groups of NIH-supported investigators to purchase or upgrade a single state-of-the-art commercially available instrument or an integrated instrumentation system. The instruments purchased through the SIG Program are required to be optimally shared among the users to ensure efficient and cost-effective research operations, enable rigorous and reproducible measurements, and encourage collaborative research and benefit broad research communities at large. The minimum award is $300,000. There is no cap on the total cost of the instrument; however, the maximum award is $5,000,000.

Research Category
External Deadline
7/27/2026

Pax Silica Artificial Intelligence Assistance Project

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language
Applicants can submit one application in response to the NOFO.  If more than one application is submitted by an organization, only the final application received, and time stamped by grants.gov will be reviewed for eligibility.  Each application can include multiple projects that will be evaluated independently.  

Priority Countries and Economies:
Australia, Costa Rica, Finland, Greece, India, Indonesia, Israel, Japan, Kazakhstan, Norway, Panama, Philippines, Qatar, Singapore, South Korea, Sweden, Taiwan, Turkiye, United Arab Emirates, United Kingdom, Vietnam

Executive Summary
Pax Silica is the Department’s flagship programmatic and policy initiative to strengthen global Artificial Intelligence (AI) supply chain security, advancing new economic security consensus among allies and trusted partners.  This U.S.-led initiative is working at speed to build a secure, resilient, innovation-driven technology ecosystem spanning critical minerals, energy, advanced manufacturing, semiconductors, AI infrastructure, and logistics.  The Pax Silica Fund, including funds appropriated to the Department of State under the International Technology Security and Innovation Fund, supports programming with partner economies that advances President Trump’s America’s AI Action Plan, Executive Order 14320 on Promoting the Export of the American AI Technology Stack, and 14179 on Removing Barriers to American Leadership in Artificial Intelligence. The Pax Fund does this by disrupting strategic competitors’ efforts to disrupt secure and reliable semiconductor supply chains and critical emerging technologies, including AI, biotechnologies, quantum, semiconductor, and space technologies. Specifically, the Pax Fund provides seed funding for innovative pilot projects to leverage international partnerships that reduce coercive dependencies, secure global technology supply chains, address AI supply chain opportunities and vulnerabilities, explore joint investment, protect sensitive technologies, and build trusted digital infrastructure. Through Pax Silica, the United States partners with the world’s most advanced economies in the strategic regions of the Indo-Pacific, Europe, the Middle East, and Latin America to outcompete strategic competitors for decades-long economic partnerships, generating multi-billion dollar deals for U.S. companies and creating thousands of American jobs with every success. Leveraging foreign assistance from the Pax Fund, this NOFO launches the Pax Silica Artificial Intelligence (AI) Assistance Project—a historic first-of-its-kind programmatic initiative to strengthen global AI supply chain security by creating a trusted supply chain credentialing and provenance platform to secure the AI supply chain in partner countries and economies. 

Funding Type
External Deadline
8/20/2026

Small Health Care Provider Quality Improvement Program

No Applicants // Limit: 1 // Tickets Available: 1

Limiting Language
You may not submit more than one application. If you submit more than one application, we will only accept the last on-time submission.

Summary
The Small Health Care Provider Quality Improvement Program supports the planning and implementation of quality improvement activities for rural primary care providers or providers of health care services, such as critical access hospitals (CAH), rural health clinics (RHC), or a network of rural health providers, to increase access to high quality health care services and improve health.

Funding Type
External Deadline
8/6/2026